摘要
目的 检测前列腺特异性膜抗原(prostate specific membrane antigen, PSMA)在前列腺癌组织中的表达情况,分析其与病人临床病理特征的关系及预后价值。方法 2015年1月~2018年9月我院诊治的前列腺癌病人280例,前列腺增生病人40例,收集石蜡切片标本,行免疫组织化学染色检测PSMA表达情况,分析与临床病理特征的相关性,采用COX比例风险模型分析影响病人无生化复发生存率(BRFS)的独立预后因子。结果 280例前列腺癌组织中,共216例(77.1%)PSMA表达阳性;40例前列腺增生组织中,17例(42.5%)PSMA表达阳性,阳性率低于前列腺癌组,差异有统计学意义(P<0.05)。存在淋巴结转移、Gleason评分>7分的病人PSMA阳性表达率较无淋巴结转移、Gleason评分≤7分高,差异有统计学意义(P<0.05)。PSMA阳性表达、淋巴结转移是影响前列腺癌病人BRFS的独立预后因子(P<0.05)。结论 前列腺癌组织中PSMA呈现高表达,与淋巴结转移、Gleason评分密切相关,可作为影响病人无生化复发生存的独立预后因子。
Objective To detect the expression of prostate specific membrane antigen(PSMA) in prostate cancer tissues, and to analyze the relationship between PSMA and clinicopathological characteristics of patients and its prognostic value.Methods Data of 280 cases of prostate cancer patients and 40 cases of prostate hyperplasia patients treated in our hospital from January 2015 to September 2018 were retrospectively analyzed.Paraffin section specimens of the patients were collected and immumohistochemical staining was performed.Using IHC to detect the expression of PSMA,and to analyze the correlation between PSMA expression and clinicopathological characteristics.Finally, Cox proportional risk model was used to analyze the independent prognostic factors affecting the biochemical relapse-free survival(BRFS) of patients.Results Of the 280 prostate cancer patients, 216 cases(77.1%) were positive for PSMA.Of the 40 cases of prostate hyperplasia, 17 cases(42.5%) were positive, and the positive rate was lower than that of the prostate cancer group(P<0.05).The positive expression rate of PSMA in patients with lymph node metastasis and Gleason score > 7 was higher than that in patients without lymph node metastasis and Gleason score ≤7,and the difference was statistically significant(P<0.05).Positive expression of PSMA and lymph node metastasis were independent prognostic factors affecting BRFS in prostate cancer patients(P<0.05).Conclusion The high expression of PSMA in prostate cancer tissues is closely related to lymph node metastasis and Gleason score, and can be used as an independent prognostic factor affecting BRFS of prostate cancer patients.
作者
季金涛
康波
苏燕胜
JI Jintao;KANG Bo;SU Yansheng(Department of Urology,986th Hospital of Air Force,Xi'an 710054,China)
出处
《临床外科杂志》
2022年第2期130-133,共4页
Journal of Clinical Surgery
关键词
前列腺癌
前列腺特异性膜抗原
预后
prostate cancer
prostate specific membrane antigen
prognosis
